Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Diabetes & Endocrinology Vol 9: 586–594  
Kosiborod M, Esterline R, Furtado M, Oscarsson J, Gasparyan S, Koch G and others
doi.org/10.1016/S2213-8587(21)00180-7